Phio Pharmaceuticals
PHIOPHIO · Stock Price
Historical price data
Overview
Phio Pharmaceuticals is a clinical-stage biotech company leveraging its proprietary INTASYL self-delivering siRNA platform to develop next-generation immuno-oncology therapies. Founded on Nobel laureate Craig Mello's RNAi discovery, the company has pivoted from discovery to development, advancing lead candidates PH-762 (PD-1 silencer) and PH-894 (BRD4 silencer) through early clinical trials. Its strategy focuses on overcoming delivery challenges in RNAi to enhance immune cell function and directly attack tumors, aiming to create synergistic treatments for cancers like cutaneous squamous cell carcinoma and melanoma.
Technology Platform
INTASYL is a proprietary self-delivering siRNA platform designed for precise gene silencing in immune and tumor cells without the need for complex delivery vehicles like lipid nanoparticles.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2 | HNSCC | Phase 1 | |
| PH-762 | Squamous Cell Carcinoma of the Skin | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes in RNAi delivery against giants like Alnylam (focused on liver) and in IO against blockbuster anti-PD-1 antibodies. Differentiates via its self-delivering siRNA platform for extra-hepatic immune/tumor targets, a niche with few direct peers but unproven clinical utility.